Clinical pharmacology study of Bramitob®, a tobramycin solution for nebulization, in comparison with Tobi®

Pediatric Drugs

Volumn 9, Issue SUPPL. 1, 2007, Pages 3-9

  Poli, Gianluigi ^a   Acerbi, Daniela ^a   Pennini, Roberto ^a   Raschini, Annamaria Soliani ^a   Corrado, Mario Ermanno ^b   Eichler, Hans Georg ^c   Eichler, Irmgard ^c  

^a CHIESI FARMACEUTICI S P A   (Italy)

^b Cross Research SA   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BRAMITOB; PLACEBO; TOBRAMYCIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FEVER; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; MALE; NEBULIZATION; NEBULIZER; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SPUTUM; URTICARIA;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CHRONIC DISEASE; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THERAPEUTIC EQUIVALENCY; TOBRAMYCIN;

EID: 34249931267     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709001-00002     Document Type: Article

References (16)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51
2. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007 Feb; 19 (1): 83-8
3. Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132: 761-5
4. Pai VB, Nahata MC. Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr Pulmonol 2001; 32: 314-27
5. British Thoracic Society. Nebuliser Project Group Guidelines. Thorax 1997; 52 Suppl. 2: S3
6. Ramsey BW. Management of pulmonary diseases in patients with cystic fibrosis. N Engl J Med 1996; 335: 179-88
7. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 2006; 31: 846-58
8. European patent n. EP 1273292 [international patent number WO 03/004005] filed on 2.07.01 and granted on 26.05.2004 [online]. Available from URL: http://www.espacenet.com/index.en.htm
9. Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolised tobramycin in cystic fibrosis. Chest 2002; 122: 219-26
10. Wood GC, Boucher BA. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000; 20: 166-81
11. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 1984; 129: 211-5
12. Knowles MR, Robinson JM, Wood RE, et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease control subjects. J Clin Invest 1997; 100: 2588-95
13. LiPuma J. Microbiological and immunologic considerations with aerosolised drug delivery. Chest 2001; 120: 118-23
14. Campbell 3rd PW, Saiman L. Use of aerosolized antibiotics in patients with cystic fibrosis. Chest 1999 Sep; 116 (3): 775-88
15. Chuchalin A, Csiszér E, Gyurkovics K, et al. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr Drugs 2007; 9 Suppl. 1: 21-31
16. Lenoir G, Antypkin YG, Miano A, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Drugs 2007; 9 Suppl. 1: 11-20